Defining cell culture dynamics in response to growth factor provision for efficient optimization of cell based therapies by Glen, Katie E et al.
 Poster Number 59 
DEFINING CELL CULTURE DYNAMICS IN RESPONSE TO GROWTH FACTOR PROVISION FOR 
EFFICIENT OPTIMIZATION OF CELL BASED THERAPIES 
 
Katie E. Glen, Loughborough University, Advanced Bioprocess Design Ltd, UK  
K.E.Glen@lboro.ac.uk 
Elizabeth A. Cheeseman, Loughborough University, Advanced Bioprocess Design Ltd, UK 
Adrian J. Stacey, Centre for Biological Engineering, Loughborough University, UK 
Robert J. Thomas, Loughborough University, Advanced Bioprocess Design Ltd, UK 
 
 
Key Words: Bioprocess, Growth factor, Optimize, Dynamic Model, Manufacture. 
 
The design of processes to manufacture Cell Based Therapies (CBTs) is particularly challenging due to the 
dynamic cell culture environment and the complex response of the cell product. An approach to process design 
needs to achieve a balance between resource spent and process knowledge gained to meet manufacturing 
goals around cost, quality and risk. In order to address this, we developed a parsimonious mathematical 
modelling framework designed to allow representation of common mechanisms in cell culture, and associated 
process operations, that drive cell culture outcomes(1). We propose that this framework can be applied to 
generate widely applicable ‘template models’ and experimental strategies for process optimization. In this case 
we have demonstrated the application to define provision rates of elements that support cell growth in a 
hematopoietic culture system (erythroblasts). Building on a model that defined the influence of environmental 
change (incorporated as a single non-specific variable linked to cell growth and density) on population growth(2), 
we have defined the cell culture dynamics in response to specific elements such as growth factor provision. We 
have shown how achieving the correct combination of delivery rates of growth factors with other factors (e.g. 
metabolic) can ensure that each is used with maximal efficiency, significantly driving down volume use (more 
than 3-fold) and process supplementation costs. The models also define the corollary of such intensification in 
terms of increasingly demanding process control with respect to volume handling and process timing; however, 
an advantage of the level of intensification achieved is that the system oxygen demand increases to a level that 
oxygen input rates can be used to identify cell growth-inhibition in advance of reduced viability. This work 
demonstrates that models that appropriately represent common process dynamics will be a key tool to achieve 
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